These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 27422891)

  • 1. Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
    Thurmond RL; Greenspan A; Radziszewski W; Xu XL; Miao Y; Chen B; Ge T; Zhou B; Baker DG; Pavlova D; Ritchlin CT; Tanaka Y; Takeuchi T; Smolen JS
    J Rheumatol; 2016 Sep; 43(9):1637-42. PubMed ID: 27422891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toreforant, an orally active histamine H
    Boyle DL; DePrimo SE; Calderon C; Chen D; Dunford PJ; Barchuk W; Firestein GS; Thurmond RL
    Inflamm Res; 2019 Apr; 68(4):261-274. PubMed ID: 30739130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
    Frankel E; Song M; Li S; Jiang J; Thurmond RL; Randazzo B
    J Drugs Dermatol; 2018 Aug; 17(8):873-879. PubMed ID: 30124726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 2a study of toreforant, a histamine H
    Kollmeier AP; Barnathan ES; O'Brien C; Chen B; Xia YK; Zhou B; Loza MJ; Silkoff PE; Ge M; Thurmond RL
    Ann Allergy Asthma Immunol; 2018 Nov; 121(5):568-574. PubMed ID: 30102965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Baricitinib in Japanese Patients with Active Rheumatoid Arthritis Receiving Background Methotrexate Therapy: A 12-week, Double-blind, Randomized Placebo-controlled Study.
    Tanaka Y; Emoto K; Cai Z; Aoki T; Schlichting D; Rooney T; Macias W
    J Rheumatol; 2016 Mar; 43(3):504-11. PubMed ID: 26834213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
    Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
    Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
    Genovese MC; Hsia E; Belkowski SM; Chien C; Masterson T; Thurmond RL; Manthey CL; Yan XD; Ge T; Franks C; Greenspan A
    J Rheumatol; 2015 Oct; 42(10):1752-60. PubMed ID: 26233509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
    Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
    Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
    Damjanov N; Tlustochowicz M; Aelion J; Greenwald M; Diehl A; Bhattacharya I; Peeva E; Menon S; Gourley I
    J Rheumatol; 2016 Dec; 43(12):2094-2100. PubMed ID: 27909139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate.
    Mease P; Strand V; Shalamberidze L; Dimic A; Raskina T; Xu LA; Liu Y; Smith J
    Ann Rheum Dis; 2012 Jul; 71(7):1183-9. PubMed ID: 22328739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate.
    Cohen SB; Moreland LW; Cush JJ; Greenwald MW; Block S; Shergy WJ; Hanrahan PS; Kraishi MM; Patel A; Sun G; Bear MB;
    Ann Rheum Dis; 2004 Sep; 63(9):1062-8. PubMed ID: 15082469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study evaluating antihistamine versus leukotriene receptor antagonist as adjuvant therapy for rheumatoid arthritis.
    Mostafa TM; Hegazy SK; El-Ghany SEA; Kotkata FAE
    Eur J Clin Pharmacol; 2021 Dec; 77(12):1825-1834. PubMed ID: 34218304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.